Cambridge's Genocea cuts staff and shelves lead drug in major shakeup
Cambridge-based Genocea Biosciences said Monday that it is laying off around 40 of its 100 employees and seeking to unload a genital herpes vaccine program as it shifts its focus to developing cancer treatments.
Genocea (Nasdaq: GNCA) said it was ceasing all spending and development activities related to GEN-003, which the company previously touted as a potential blockbuster. Genocea said it was “exploring strategic alternatives” for the vaccine, typically shorthand for a sale or other transaction.
T he…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Max Stendahl Source Type: news
More News: American Health | Cancer | Cancer & Oncology | Cancer Vaccines | Genital Herpes | Health Management | Herpes | Vaccines